Work from the Huberman Laboratory at Stanford School of Medicine has been published in top journals, including Nature, Science, and Cell, and has been featured in TIME, BBC, Scientific American, Discover, and other top media outlets
In mammals, GSTs exist as homodimers with analogous tertiary structures [202]
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)
Cassiopea Glenmark Pharmaceuticals Sources Primary Research Interviews Pharmaceutical manufacturers and drug developers Healthcare providers and endocrinologists Regulatory affairs specialists Pharmaceutical distributors and retailers Others Magazines Pharmaceutical Executive BioPharma Dive Diabetes Care Magazine Drug Discovery & Development Others Journals Pharmaceutical Executive BioPharma Dive Diabetes Care Magazine Drug Discovery & Development Others Newspapers Financial Times The Wall Street Journal Reuters Health News Bloomberg Healthcare Others Associations American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) International Diabetes Federation (IDF) Pharmaceutical Research and Manufacturers of America (PhRMA) Others Public Domain Sources World Health Organization (WHO) publications Centers for Disease Control and Prevention (CDC) reports European Medicines Agency (EMA) publications National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Others Proprietary Elements CMI Data Analytics Tool GLP-1 Receptor Agonist Market CMI Existing Repository of Information for the Last 8 Years * Definition: Global GLP-1 receptor agonist market involves pharmaceutical products that mimic the effects of naturally occurring glucagon-like peptide-1 (GLP-1)
Dobberfuhl, A
Understanding which peptide does what, and why, is the foundation for evaluating their potential in autoimmune research
